by Denkstrom
All storiesInvika shows preliminary antitumor activity in study

Invika shows preliminary antitumor activity in study

Researchers report initial results from the START-001 clinical trial of Invika. At the two biologically optimal doses, 4 of 27 treated patients with solid tumors had an objective response, including patients with tumor types classified as immunologically cold.

At the two doses described as biologically optimal, 0.08 and 0.12 milligrams per kilogram, the objective response rate was 14.8 percent. These included confirmed partial remissions in microsatellite-stable colorectal cancer and PD-L1-negative non-small cell lung cancer, two tumor types the study authors classify as immunologically cold.

How the drug works and what it has shown so far

According to the study authors, invikafusp alfa is a bispecific, dual T-cell agonist antibody that selectively activates so-called Vβ6/Vβ10 T cells, a subset of immune cells that infiltrate tumors. The drug was tested as monotherapy in patients with antigen-rich solid tumors, most of which were resistant to immune checkpoint blockade. The primary endpoints of phase 1 were safety and determination of the recommended phase 2 dose, while the primary endpoint in phase 2 was antitumor activity. By the data cutoff date of March 12, 2025, 34 participants had undergone dose escalation without a maximum tolerated dose being reached; 18 patients had been enrolled in the initial phase 2. The authors observed no objective response below 0.08 milligrams per kilogram. Two participants experienced reversible dose-limiting side effects, one each at 0.08 and 0.16 milligrams per kilogram. The most common treatment-related side effect was cytokine release syndrome, predominantly grade 1 or 2; no treatment-related deaths or grade 4 events outside laboratory findings were reported.

cancer research

Analysis at the ESMO congress in Madrid

Among 62 evaluable patients with heavily pretreated, mutation-rich tumors across eight cancer types, including breast, colorectal, stomach and lung cancer, Marengo Therapeutics recorded tumor shrinkage in 56 percent, an objective response rate of 18 percent and a disease control rate of 60 percent. Among patients who had previously received immune checkpoint blockade, the response rate and disease control rate were higher than among patients who had not received such prior treatment, at 20 versus 14 percent and 68 versus 43 percent, respectively. Among 104 patients assessed for safety, cytokine release syndrome remained predominantly grade 1 or 2, according to Marengo, and no immune effector cell-associated neurotoxicity syndrome or fatal treatment-related events were observed. Invikafusp alfa received Fast Track designation from the FDA in January 2025 for TMB-high colorectal cancer, followed by an expansion in October 2026 to TMB-high solid tumors regardless of tissue of origin.

immunotherapy

In comparison: two analyses, one study

The two datasets differ: The journal publication assessed 27 patients at the optimal doses, with a data cutoff of March 12, 2025, while the separate ESMO analysis includes 62 evaluable TMB-H patients. Both analyses also report figures of a similar magnitude: According to AABB, 59.3 percent had no disease progression, while the disease control rate in the ESMO analysis, which also includes disease that is merely stable, was 60 percent. The study is open-label and non-randomized and was last registered as recruiting, with an estimated total of 366 participants, according to the ClinicalTrials.gov study registry; there is no comparison group without the drug. The sponsor is Marengo Therapeutics, which is developing invikafusp alfa; several study authors are employees of the company, according to Cancer Health, while co-author Ryan J. Sullivan also received institutional research funding from Marengo and other manufacturers and served as a consultant or advisory board member for several of them. How many of the estimated 366 participants have actually been assessed so far, and how long do the responses observed to date last?

What is still needed

In the study authors' assessment, phase 1 met its primary endpoints, with a safety profile considered acceptable and the selection of 0.08 milligrams per kilogram as the recommended phase 2 dose. In their view, the initial phase 2 data confirmed safety and added to the preliminary evidence of clinically meaningful activity in solid tumors resistant to immune checkpoint blockade, which they believe supports the ongoing phase 2. Co-author Ryan Sullivan said further studies were needed to understand which patients should be treated with invikafusp. Co-first author Nicholas Tschernia called it new and exciting to see activity in patients whose cancer had stopped responding to immunotherapy, a group with very few remaining options, according to AABB. According to Marengo Therapeutics, a more complete clinical dataset is expected in 2027, while duration of response and overall survival are specified as endpoints in the study registry, with a follow-up period of up to three years. According to company information dated October 15, 2026, invikafusp alfa remains an unapproved investigational drug.